1 hr ago
4 Paws for Ability Joins Eisai at 8th Annual National Walk for...
Eisai, a long-time supporter of the Epilepsy Foundation, will be joined at the walk by 4 Paws for Ability , a non-profit organization focused on the training and placement of service dogs for children with a variety of conditions, including epilepsy.
Eisai Announces President And CEO Succession
Eisai Inc . announced the appointment of Yuji Matsue as company chairman and chief executive officer and Shaji Procida as president and chief operating officer, succeeding current President and CEO Lonnel Coats.
Eisai Inc.'s President And CEO To Retire
In his role as chairman and CEO, Mr. Matsue will be responsible for the strategic direction of the Americas Region.
Eisai President and CEO to Retire
Eisai Inc. has announced the appointments of Yuji Matsue as chairman and chief executive officer and Shaji Procida as president and chief operating officer, effective April 1, 2014.
Eisai Inc. Announces Initiation Of A Phase 3 Trial Of Eribulin...
Eisai Inc. Announces Initiation Of A Phase 3 Trial Of Eribulin Mesylate Injection Versus Weekly Paclitaxel In First And Second Lines Of Metastatic Breast Cancer /PRNewswire/ -- Eisai Inc. today announced the start of a large, randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel ... (more)
ACCRU Launches Trial Comparing Eribulin to Paclitaxel for Recurrent or Metastatic Breast Cancer
Academic and Community Cancer Research United today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 negative, locally recurrent, unresectable or metastatic breast ... (more)